Abstract
A cross-section of clinical research professionals convened at the June 2016 Drug Information Association annual meeting in Philadelphia to discuss and critically analyze the first-in-human (FIH) clinical trial conducted by a French CRO with BIA 10-2474 (BIA) under development for pain relief by Bial-Portela & Ca., S.A., that resulted in 6 healthy volunteers hospitalized with serious adverse events, which resulted in 1 death. This paper summarizes the background, presentations, and discussion points of Symposium no. 107 in an effort to share the learnings of our symposium with others who conduct studies. Novel investigational products studied in phase 1 clinical trials propose a heightened risk of adverse events that may not be foreseeable when relying on animal studies to project outcomes in humans. Novelty of molecular structure, drug class, mechanism of action, proper dose selection, pharmacokinetics, and therapeutic window are all contributing factors that heighten risks when transitioning from animal to human trials. The potential for catastrophic events confronts every sponsor/investigator in clinical trials. Minimizing risks to subjects is an essential ethical and scientific mandate for all those involved in the clinical trials. A complex matrix of planning, conducting, and communicating preclinical and clinical observations need to be considered carefully by the Sponsor, Investigator and others during the planning, execution, and interpretation of FIH studies, in order to promote participant safety and study data integrity. Suggestions may be applied to FIH studies, which may provide a new or improved way to address complex system and prevent or mitigate situations such as what occurred with the Bial FIH trial, where seemingly a number of issues coincided in a “perfect storm” and the system failed to sound a warning or detect an issue before a life was tragically lost.
References
Suntharalingam G. Cytokine storm in a phase 1 trial of the Anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018–1028.
Expert Scientific Group on Phase One Clinical Trials, Final Report, 30-Nov-2006. http://www.dh.gov.uk/assetRoot/04/14/10/43/04141043.pdf.
Guideline on strategies to identify and mitigate risks for first-in human clinical trials with investigational medicinal products EMEA/CHMP/SWP/28367/07. July 19, 2007.
First in human studies: points to consider in study placement, design and conduct. http://www.abpi.org.uk/our-work/library/guidelines/Documents/First%20in%20Human%20Studies.pdf.
Emanuel EJ. Quantifying the risks of non-oncology phase I research in healthy volunteers: meta-analysis of phase I studies. BMJ. 2015;350:h3271.
Hawkes N. French drug trial protocol fails to answer key questions. BMJ. 2016;352:i466.
Eddleston M. Implications of the BIA-102474-101 study for review of first-into-human clinical trials. Br J Clin Pharmacol. 2016;81:582–586.
Cohen A. “Should we tolerate tolerability as an objective in early drug development?” Br J Clin Pharmacol. 2007;64:249–252.
Report by the Temporary Specialist Scientific Committee (TSSC), “FAAH (Fatty Acid Amide Hydrolase),” on the causes of the accident during a phase 1 clinical trial in Rennes in January 2016. Saint-Denis, France: Agence Nationale de Sécurité du Médicament et des Produits de Santé. http://ansm.sante.fr/var/ansm_site/storage/original/application/744c7c6daf96b141bc9509e2f85c227e.pdf.
FDA Guidance to Industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers, July 2005.
Swiss cheese model. Wikipedia. https://en.wikipedia.org/wiki/Swiss_cheese_model.
Reason J. Human error: models and management. BMJ. 2000;320:768–770.
Gawande A. The checklist manifesto: How to get things right. http://atulgawande.com/book/the-checklist-manifesto/.
Leveson N, Daouk M, Dulac N, Marais K. Applying STAMP in accident analysis. https://shemesh.larc.nasa.gov/iria03/p13-leveson.pdf.
MIT Partnership for a Systems Approach to Safety (PSAS). 2016 STAMP Workshop Presentations. http://psas.scripts.mit.edu/home/2016-stamp-workshop-presentations/.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Greenberg, H.E., van Iersel, M.T., Westrick, M.L. et al. Safety in FIH Trials: A Summary of the Symposium “Fatal Drug Trial in Phase 1: Understanding Risk, Subject Safety, Timelines, and Cost”. Ther Innov Regul Sci 51, 276–284 (2017). https://doi.org/10.1177/2168479017706404
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479017706404